Keryx Suffers Setback As Diabetic Nephropathy Candidate Fails Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm falls back on mid-stage pipeline candidates in chronic kidney disease, kidney cancer.